Back to News
Market Impact: 0.12
Scynexis Names Sanjay Subramanian CFO
Source: Nasdaq
Management & GovernanceHealthcare & Biotech
Scynexis appointed Sanjay Subramanian as chief financial officer, effective September 9. The executive change is a routine governance development for the clinical-stage rare-disease biotechnology company, with no financial results, strategy changes, or guidance disclosed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.05
Ticker Sentiment
SCYX0.15
More News
- Biotech stocks are surging. How investors can play the new drug innovation boom
- IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER
- Thousands of Israelis rally against Netanyahu gov’t days before election
- ‘There’s nothing temporary about a temporary store’: How Spirit Halloween’s CEO took it from 130 stores to 1,550—and swallowed your mall’s Hot Topic
- J&J prostate cancer drug shows promising tumor responses in early trial
- Pfizer reports phase 2 data for 25-valent pneumococcal vaccine